The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Substituted phenethylamines are a chemical class of organic compounds based upon the phenethylamine structure; the class is composed of all the derivative compounds of phenethylamine which can be formed by replacing, or substituting, one or more hydrogen atoms in the phenethylamine core structure with substituents. Many substituted phenethylamines are psychoactive drugs, which belong to a variety of different drug classes, including central nervous system stimulants (e.g., amphetamine), hallucinogens (e.g., 2,5-dimethoxy-4-methylamphetamine), entactogens (e.g., 3,4-methylenedioxyamphetamine), appetite suppressants (e.g. phentermine), nasal decongestants and bronchodilators (e.g., pseudoephedrine), antidepressants (e.g. bupropion), antiparkinson agents (e.g., selegiline), and vasopressors (e.g., ephedrine), among others. Many of these psychoactive compounds exert their pharmacological effects primarily by modulating monoamine neurotransmitter systems; however, there is no mechanism of action or biological target that is common to all members of this subclass. Numerous endogenous compounds—including hormones, monoamine neurotransmitters, and many trace amines (e.g., dopamine, norepinephrine, adrenaline, tyramine, and others)—are substituted phenethylamines. Dopamine is simply phenethylamine with a hydroxyl group attached to the 3 and 4 position of the benzene ring. Several notable recreational drugs, such as MDMA (ecstasy), methamphetamine, and cathinones, are also members of the class. All of the substituted amphetamines are phenethylamines, as well.
Potassium is a chemical element; it has symbol K (from Neo-Latin kalium) and atomic number 19. It is a silvery white metal that is soft enough to easily cut with a knife. Potassium metal reacts rapidly with atmospheric oxygen to form flaky white potassium peroxide in only seconds of exposure. It was first isolated from potash, the ashes of plants, from which its name derives. In the periodic table, potassium is one of the alkali metals, all of which have a single valence electron in the outer electron shell, which is easily removed to create an ion with a positive charge (which combines with anions to form salts). In nature, potassium occurs only in ionic salts. Elemental potassium reacts vigorously with water, generating sufficient heat to ignite hydrogen emitted in the reaction, and burning with a lilac-colored flame. It is found dissolved in seawater (which is 0.04% potassium by weight), and occurs in many minerals such as orthoclase, a common constituent of granites and other igneous rocks. Potassium is chemically very similar to sodium, the previous element in group 1 of the periodic table. They have a similar first ionization energy, which allows for each atom to give up its sole outer electron. It was first suggested in 1702 that they were distinct elements that combine with the same anions to make similar salts, which was demonstrated in 1807 when elemental potassium was first isolated via electrolysis. Naturally occurring potassium is composed of three isotopes, of which 40K is radioactive.
== Human and mouse genes == The genes encoding human 5-HT3 receptors are located on chromosomes 11 (HTR3A, HTR3B) and 3 (HTR3C, HTR3D, HTR3E), so it appears that they have arisen from gene duplications. The genes HTR3A and HTR3B encode the 5-HT3A and 5-HT3B subunits and HTR3C, HTR3D and HTR3E encode the 5-HT3C, 5-HT3D and 5-HT3E subunits. HTR3C and HTR3E do not seem to form functional homomeric channels, but when co-expressed with HTR3A they form heteromeric complex with decreased or increased 5-HT efficacies. The pathophysiological role for these additional subunits has yet to be identified. The human 5-HT3A receptor gene is similar in structure to the mouse gene which has 9 exons and is spread over ~13 kb. Four of its introns are exactly in the same position as the introns in the homologous α7-acetylcholine receptor gene, clearly showing their evolutionary relationship.
==== Triglyceride ==== In this process, green coffee beans are soaked in a hot water and coffee solution to draw the caffeine to the surface of the beans. Next, the beans are transferred to another container and immersed in coffee oils that were obtained from spent coffee grounds and left to soak. After several hours of high temperatures, the triglycerides in the oils remove the caffeine, but not the flavor elements, from the beans. The beans are separated from the oils and dried. The caffeine is removed from the oils, which are reused to decaffeinate another batch of beans. This is a direct-contact method of decaffeination.
When this infusion of citric acid cycle intermediates exceeds cataplerotic demand (such as for aspartate or glutamate synthesis), some of them can be extracted to the gluconeogenesis pathway, in the liver and kidneys, through phosphoenolpyruvate carboxykinase, and converted to free glucose.
Sources: en.wikipedia.org
The new 3rd district encompasses much of Collin County and Hunt County in the Dallas–Fort Worth Metroplex, including eastern Plano, McKinney, Allen, Wylie and Greenville, as well as much of the I-30 corridor to the east including Sulphur Springs and Mount Pleasant. The incumbent is Republican Keith Self, who was re-elected with 62.5% of the vote in 2024. Donald Trump and Ted Cruz each respectively won 60.3% and 57.7% of the vote here in 2024.
Type I : Extra-dural; no nerve roots or rootlets such as intra-sacral meningoceles; probably of congenital origin developing from the dural sac to which they are connected by a little collar. They are found at the point of exit of a dorsal nerve root from the dural sac. They are sometimes difficult to identify and can be "seen" as a type II cyst on imaging. These cysts are often associated with foramina enlargement and scalloping of the vertebrae. It is very important to distinguish them from sacral meningoceles going to the pelvic area; they are often associated with other congenital abnormalities (teratomes, dermoïdes, lipomas, and other abnormalities(uro-genital and ano-rectal)) Type II: Extra-dural; nerve root present (such as Tarlov or perineural cysts). There are often not only one but multiple cysts, mostly found in the sacrum area. There are two types: Tarlov (perineural) cysts are located posteriorly to the root ganglion, with nerve fibres inside or nerve tissue in the walls; they are not communicating with the perineural arachnoid space. Type-II cysts are very small in the upper sacral area, but can be bigger (up to 3 centimetres or 1.2 inches) if found located in the lower part of the sacrum. The second variant of type-II cysts are called "meningeal diverticula". They are located anteriorly to the nerve root ganglion, with nerves fibres inside and communicating with the subarachnoid space. Type III: intra-dural; these are either congenital or caused by trauma; they are rarely associated with other abnormalities and rare in occurrence.
=== Discontinued === Alniditan (R-91274) – serotonin 5-HT1B and 5-HT1D receptor agonist – migraine [72] Avitriptan (BMS-180048) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [73] Bezisterim (HE-3286; NE-3107; Triolex; 17α-ethynyl-5-androstene-3β,7β,17β-triol) – undefined mechanism of action (synthetic androstenetriol analogue and anti-inflammatory) – migraine [74] BI-44370 (BI44370) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [75] Botulinum toxin A topical (RT-001) – acetylcholine release inhibitor and neuromuscular blocking agent – migraine [76] Carisbamate (Comfyde; JNJ-10234094; RWJ-333369; YKP-509) – unknown mechanism of action – migraine [77] Dasolampanel (NGX-426) – ionotropic glutamate AMPA and kainate receptor antagonist – migraine [78] Dextromethorphan/quinidine (DXM/Q; AVP-923; Neurodex; Nuedexta; Zenvia) – combination of dextromethorphan (various actions) and quinidine (various actions) – migraine [79] Dihydroergocryptine (SRN-001) – non-selective monoamine receptor modulator and ergoline – migraine [80] Donitriptan (F-11356) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [81] Dotarizine (Dotaricin; FI-6026) – calcium channel blocker and serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptor antagonist – migraine [82] Dronabinol (Δ9-THC; Δ9-tetrahydrocannabinol; Deltanyne; Elevat; Marinol) – cannabinoid CB1 and CB2 receptor agonist – migraine [83] Ergotamine inhalation (Tempo-ergotamine) – non-selective monoamine receptor modulator and ergoline – migraine [84] Esprolol ((S)-ACC-9369) – beta blocker (β-adrenergic receptor antagonist) (amoxolol prodrug) – migraine [85] Ethinylestradiol/levonorgestrel (DP3; DR-103; DR-105; LoSeasonique; Seasonique) – combination of ethinylestradiol (an estrogen) and levonorgestrel (a progestogen) and a combined oral contraceptive – menstrual migraine [86] (S)-Ethylisothiouronium diethylphosphate (Difetur; MTR-104; MTR-105; MTR-106; MTR-107; MTR-108; Raviclust; Ravimig; Raviten) – nitric oxide synthase (NOS) inhibitor [87] Fremanezumab (Ajovy; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – cluster headache, headache [88] Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) – migraine [89] Gabapentin enacarbil (1838262; ASP8825; GSK-1838262; Horizant; Regnite; Solzira; XP13512) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) – migraine [90] Ganaxolone (CCD-1042; Ztalmy) – GABAA receptor positive allosteric modulator and neurosteroid – migraine [91] HTL-0022562 (BHV-3100; HTL-22562) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [92] IS-159 – serotonin 5-HT1B and 5-HT1D receptor agonist – migraine [93] Lacosamide (ADD-234037; Erlosamide; Harkoseride; SPM-927; SPM-929; Vimpat; Vimpato) – various actions – migraine [94] Lanepitant (LY-303870) – neurokinin NK1 receptor antagonist – migraine [95] Lidocaine transdermal patch (ADL-87223; LidoPAIN) – sodium channel blocker – headache [96] Lornoxicam (Bosporon; Chlortenoxicam; HN-10000; RO-139297; Safem; TS-110; Xefo) – COX inhibitor/NSAID – migraine [97] LY-2300559 – metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator and cysteinyl leukotriene receptor 1 (CysLTR1) antagonist – migraine [98] LY-334370 – serotonin 5-HT1F receptor agonist and triptan – migraine [99] MEDI-0618 – monoclonal antibody against protease-activated receptor 2 (PAR2) – migraine [100] Olcegepant (BIBN-4096; BIBN-4096BS) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [101] Oxytocin (TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – migraine [102] Perampanel (E-2007; ER-155055-90; Fycompa) – AMPA receptor antagonist – migraine [103] PF-5180999 (PF-05180999) – phosphodiesterase PDE2 inhibitor – migraine [104] PNU-142633 (PNU-142633F) – serotonin 5-HT1D receptor agonist – cluster headache, headache, migraine [105] Prochlorperazine inhalation (AZ-001) – typical antipsychotic (non-selective monoamine receptor modulator) – migraine [106] Propisergide (ergalgin) – serotonin receptor modulator and ergoline – migraine Propofol phosphate (Neuprox; propofol prodrug) – GABAA receptor positive allosteric modulator (propofol prodrug) – migraine [107] Research programme: migraine therapy - Orexo (OX-40; OX641) – undefined mechanism of action – migraine [108] Selurampanel (BGG-492; BGG-492A) – ionotropic glutamate AMPA and kainate receptor antagonist – migraine [109] Sergolexole (LY-281067) – serotonin 5-HT2 receptor antagonist and ergoline – migraine [110] Telcagepant (MK-0974) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [111] Tezampanel (LY-293558; NGX-424; PRN-001-01) – ionotropic glutamate AMPA and kainate receptor antagonist – migraine [112] Tizanidine (AN-021A; AN-021; DS-103282; Sirdalud; Ternelin; Zanaflex) – α2-adrenergic receptor agonist – migraine [113] Tonabersat (SB-220453; USL-260; Xiflam) – connexin 43 (GJA1) inhibitor – migraine [114] Zolmitriptan inhalation (CVT-427) – serotonin 5-HT1B and 5-HT1D receptor agonist and triptan – migraine [115] Zonisamide (AD-810; CI-912; Excegran; Kinaplase; PD-110843; Tremode; Trerief; Zonegran) – calcium channel blocker, sodium channel blocker, and other actions – migraine [116]
Once again, RuBisCO activase can promote the release of these analogs from the catalytic sites and maintain the enzyme in a catalytically active form. However, at high temperatures, RuBisCO activase aggregates and can no longer activate RuBisCO. This contributes to the decreased carboxylating capacity observed during heat stress.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.